Drug interactions with apixaban
Pro Research Analysisby 
Searched over 200M research papers
Overview of Apixaban Drug Interactions
Apixaban, a direct oral anticoagulant, is often considered to have a lower risk of drug-drug interactions compared to older anticoagulants, but significant interactions can still occur, especially with drugs affecting its metabolism or those that impact bleeding risk Fernandez2020Badreldin2020Favatella2024.
Pharmacokinetic Interactions: CYP3A4 and P-gp Modulators
Apixaban is metabolized by the liver enzyme CYP3A4 and is a substrate for the P-glycoprotein (P-gp) transporter. Drugs that inhibit or induce these pathways can alter apixaban levels in the body:
- Inhibitors (Increase Apixaban Levels): Strong inhibitors like cobicistat (an antiretroviral) and amiodarone can significantly increase apixaban concentrations, raising the risk of bleeding Ammar2021Milner2022Gulilat2019. Amiodarone, in particular, has been shown to increase apixaban levels in patients with atrial fibrillation .
- Inducers (Decrease Apixaban Levels): Drugs such as primidone (a CYP3A4 inducer) can lower apixaban exposure, potentially reducing its effectiveness and increasing the risk of thrombosis Manis2023Favatella2024.
- Other Notable Interactions: Cyclosporine (a combined CYP3A4, P-gp, and BCRP inhibitor) increases apixaban levels, while tacrolimus (another immunosuppressant) may decrease them, but these changes are generally not large enough to require dose adjustments .
Pharmacodynamic Interactions: Bleeding and Thrombosis Risk
Many drug interactions with apixaban are pharmacodynamic, meaning they affect the drug’s action rather than its concentration:
- Increased Bleeding Risk: The most common and serious interactions are with other drugs that impair hemostasis, such as antiplatelet agents (e.g., aspirin), non-steroidal anti-inflammatory drugs (NSAIDs), and some antidepressants. These combinations can significantly increase the risk of gastrointestinal and other types of bleeding Fernandez2020Badreldin2020Svalastoga2025.
- Cancer Patients: In patients with cancer, who often take multiple medications, most interacting drugs did not clearly affect major clinical outcomes, except for fluconazole, which may increase the risk of non-major bleeding .
New and Emerging Drug Interactions
Recent studies have shown that certain antitumor drugs, such as adagrasib and asciminib, can inhibit the metabolism of apixaban, leading to higher drug levels and potentially increased bleeding risk. These findings highlight the need for careful monitoring when new medications are introduced .
Real-World Prevalence and Clinical Management
In real-world settings, nearly half of patients with non-valvular atrial fibrillation on apixaban are exposed to potential drug interactions, with many involving medications that may not be clinically necessary. Regular review of all medications and appropriate dose adjustments are important to minimize risks Badreldin2020Favatella2024.
Genetic and Patient-Specific Factors
Genetic differences, such as variants in the ABCG2 gene, can also affect apixaban concentrations, especially when combined with interacting drugs like amiodarone. Patient factors such as age, weight, and kidney function further influence drug levels and should be considered in clinical decisions .
Conclusion
While apixaban generally has a favorable interaction profile, significant drug-drug interactions can occur, especially with CYP3A4 and P-gp modulators and drugs that affect bleeding risk. Careful medication review, awareness of new drug interactions, and consideration of patient-specific factors are essential for safe and effective use of apixaban Fernandez2020Bashir2018Shen2024+7 MORE.
Sources and full results
Most relevant research papers on this topic